imiquimod has been researched along with Granulocytic Leukemia, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biedrzycki, B; Chia, C; Garrett-Mayer, E; Gocke, C; Harding, TC; Hege, K; Jones, R; Kasamon, YL; Kowalski, J; Levitsky, HI; Miller, CB; Murphy, K; Qin, L; Smith, BD; Tsai, HL; Tu, GH | 1 |
| Ichim, TE; Lipton, JH; Marleau, AM; Riordan, NH | 1 |
1 review(s) available for imiquimod and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Therapeutic use of Aldara in chronic myeloid leukemia.
Topics: Adaptive Immunity; Adjuvants, Immunologic; Aminoquinolines; Humans; Imiquimod; Immunity, Innate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2007 |
1 trial(s) available for imiquimod and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
Topics: Adult; Aged; Aminoquinolines; Benzamides; Cancer Vaccines; Female; Fusion Proteins, bcr-abl; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Imiquimod; Immunotherapy; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Piperazines; Pyrimidines; Tumor Burden | 2010 |